Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02856451 · ClinicalTrials.gov registry record
Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 486
- Enrollment target
NCT02856451 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 486 participants.
The verdict
NCT02856451 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 486 participants
- Enrollment target
Study Summary
A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.
Interventions
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 486 participants |
| Start Date | 2015-12-09 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02856451
The ClinicalTrials.gov registry entry for NCT02856451 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 486 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT02856451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02856451 about?
NCT02856451 is a clinical study titled "Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab". A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.
What is the current status of trial NCT02856451?
This trial is currently completed. The enrollment target is 486 participants. The study started on 2015-12-09. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT02856451?
The interventions under investigation include: Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02856451?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.